China Eliminates Import Tax on Indian Pharma

China has slashed its 30% import duty on Indian medicines to zero, removing customs barriers and enabling smoother exports. The policy change is expected to unlock billions in potential revenue for India’s pharmaceutical sector, reshaping global trade dynamics and enhancing the reach of affordable Indian drugs.

Opportunities Amid U.S. Tariff Pressures
The move comes as U.S. President Donald Trump imposes a 100% tariff on pharmaceutical imports, threatening India’s $25+ billion export industry. With the U.S. market becoming less lucrative, China’s decision offers Indian pharma companies a huge opportunity to access its growing healthcare market and diversify their global revenue streams.

Impact on Indian Pharma and Global Trade
The tariff removal strengthens India’s position as the “pharmacy of the world,” enabling competitive pricing and wider market presence in China. Experts expect increased manufacturing, thousands of new jobs, and a more balanced India-China trade relationship, solidifying India’s influence in global healthcare supply chains and affordable medicine production.